| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
|
Leukemia
|
2009
|
4.91
|
|
2
|
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
|
Blood
|
1998
|
3.69
|
|
3
|
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.
|
Nat Genet
|
1997
|
3.11
|
|
4
|
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.
|
Proc Natl Acad Sci U S A
|
2000
|
2.81
|
|
5
|
Genetic aberrations and survival in plasma cell leukemia.
|
Leukemia
|
2008
|
2.69
|
|
6
|
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
|
Blood
|
2001
|
2.48
|
|
7
|
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
|
Blood
|
1998
|
2.36
|
|
8
|
Multiple myeloma: increasing evidence for a multistep transformation process.
|
Blood
|
1998
|
2.29
|
|
9
|
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
|
Blood
|
1996
|
2.21
|
|
10
|
Genetic events in the pathogenesis of multiple myeloma.
|
Best Pract Res Clin Haematol
|
2007
|
2.14
|
|
11
|
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
|
Leukemia
|
2011
|
2.12
|
|
12
|
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.
|
Cancer Res
|
2001
|
2.12
|
|
13
|
Benzene and multiple myeloma: appraisal of the scientific evidence.
|
Blood
|
1999
|
2.05
|
|
14
|
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
|
Leukemia
|
2009
|
1.97
|
|
15
|
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
|
Leukemia
|
2010
|
1.77
|
|
16
|
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
|
Leukemia
|
2006
|
1.71
|
|
17
|
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
|
Leukemia
|
2007
|
1.66
|
|
18
|
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy.
|
Leukemia
|
2008
|
1.43
|
|
19
|
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
|
Leukemia
|
2006
|
1.39
|
|
20
|
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
|
Leukemia
|
2008
|
1.24
|
|
21
|
Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
|
Blood
|
2000
|
1.21
|
|
22
|
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
|
Leukemia
|
2013
|
1.21
|
|
23
|
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.
|
Leukemia
|
2007
|
1.18
|
|
24
|
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.
|
Blood
|
2001
|
1.17
|
|
25
|
Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.
|
Mol Cell
|
1999
|
1.16
|
|
26
|
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
|
Leukemia
|
2002
|
1.15
|
|
27
|
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
|
Blood
|
2001
|
1.15
|
|
28
|
Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
|
Blood
|
2000
|
1.09
|
|
29
|
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.
|
Leukemia
|
2010
|
0.97
|
|
30
|
Selective expression of one c-myc allele in two human myeloma cell lines.
|
Cancer Res
|
1996
|
0.95
|
|
31
|
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.
|
Leukemia
|
2007
|
0.92
|
|
32
|
CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements.
|
Blood
|
1997
|
0.91
|
|
33
|
Expression and mutation status of candidate kinases in multiple myeloma.
|
Leukemia
|
2007
|
0.87
|
|
34
|
Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.
|
Ann Oncol
|
2000
|
0.87
|
|
35
|
Dysregulation of c-myc in multiple myeloma.
|
Curr Top Microbiol Immunol
|
1997
|
0.85
|
|
36
|
Multiple myeloma.
|
Hematology Am Soc Hematol Educ Program
|
2001
|
0.84
|
|
37
|
Maintained rules of development in a mouse B-cell tumor.
|
Leukemia
|
2005
|
0.84
|
|
38
|
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
|
Cell Death Dis
|
2013
|
0.83
|
|
39
|
Ploidy status rarely changes in myeloma patients at disease progression.
|
Leuk Res
|
2005
|
0.81
|
|
40
|
Coordinate silencing of myeloma-specific genes in myeloma x T lymphoma hybrids.
|
J Immunol
|
1993
|
0.81
|
|
41
|
Initiation and maintenance of multiple myeloma.
|
Semin Hematol
|
1999
|
0.77
|
|
42
|
Identification of consensus genes expressed in plasmacytomas but not B lymphomas.
|
Curr Top Microbiol Immunol
|
1990
|
0.75
|